Dynorphin A
dynorphin A(1-17), dynorphin, PDYN gene product, dynorphin A(1-13)
Dynorphin A is the principal endogenous kappa-opioid receptor ligand, derived from prodynorphin. Unlike the mu-opioid system it is associated with dysphoria, aversion and stress rather than euphoria, and it is central to current thinking about the aversive component of stress and withdrawal. Human therapeutic evidence for the peptide itself is old, small and poor.
Mechanism
Prodynorphin is processed to dynorphin A, dynorphin B and alpha- and beta-neoendorphin, all sharing the leu-enkephalin N-terminus. Dynorphin A binds kappa-opioid receptors with high affinity and selectivity, coupling through Gi/Go to inhibit adenylate cyclase, open GIRK channels and close calcium channels; kappa signalling also recruits beta-arrestin and activates p38 MAPK, a pathway implicated specifically in the dysphoric and aversive effects and now a target for biased-agonist design. Kappa activation in the ventral tegmental area and nucleus accumbens suppresses dopamine release, the mechanistic mirror image of mu-opioid reward.
Dynorphin A also has well-documented non-opioid actions that are not blocked by naloxone, including NMDA receptor modulation and, at high spinal concentrations, neurotoxicity and paradoxical hyperalgesia. Prodynorphin expression is strongly upregulated by stress through corticotropin-releasing factor signalling, and by chronic drug exposure, which is why the dynorphin-kappa system is treated as an endogenous anti-reward mechanism contributing to the negative affective state of withdrawal.
What the research shows
Dynorphin A(1-13) was administered in small human studies of opioid detoxification and analgesia decades ago, mostly open-label and underpowered, with results that were never confirmed. Nothing in that literature meets modern standards and no reliable citation for it could be verified, so it is described here but not cited. There is no current clinical development of the peptide.
The more informative recent evidence concerns kappa antagonism, on the hypothesis that blocking dynorphin signalling should relieve anhedonia and depression. A well-conducted 89-patient phase 2a trial showed that a selective kappa antagonist significantly increased ventral striatal activation during reward anticipation, its prespecified imaging primary outcome; that is proof of mechanism, not proof of clinical benefit, and the trial was explicitly designed as such. The subsequent clinical programmes disappointed: navacaprant failed to separate from placebo on its primary endpoint in major depressive disorder, and aticaprant development for adjunctive treatment of depression was discontinued for insufficient efficacy. Conversely, kappa agonists have been limited throughout by dysphoria, sedation and hallucination, restricting them to peripherally restricted compounds such as difelikefalin for pruritus. The dynorphin-kappa system is real and important, but it has so far proved a difficult therapeutic target in both directions.
Evidence assessment
Limited evidence
No modern controlled trial has administered dynorphin A to humans, and the 1980s and 1990s dynorphin A(1-13) work is uncontrolled and uncited here because no reliable identifier could be confirmed. The human evidence retained tests kappa antagonists, not the peptide: one phase 2a proof-of-mechanism trial met an imaging endpoint but not a clinical one, and later phase 3 antagonist programmes failed.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Dynorphin-(1-13), an extraordinarily potent opioid peptide Preclinical only
Identified dynorphin as an exceptionally potent opioid peptide, orders of magnitude more potent than leu-enkephalin in the guinea-pig ileum assay.
Dynorphin is a specific endogenous ligand of the kappa opioid receptor Preclinical only
Established dynorphin as the endogenous kappa ligand, explaining how a leu-enkephalin-containing peptide achieves kappa rather than delta selectivity.
The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system Preclinical only
Stress-induced aversion required corticotropin-releasing factor-driven dynorphin release and kappa activation, establishing the anti-reward framework. Rodent data only.
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating kappa-opioid antagonism as a treatment for anhedonia Preclinical only
The kappa antagonist significantly increased fMRI ventral striatum activation during reward anticipation, the prespecified primary outcome (effect size 0.58). This is a target-engagement and mechanism result, not a demonstration of clinical antidepressant efficacy.
Navacaprant in major depressive disorder (KOASTAL programme) Preclinical only
The selective kappa antagonist failed to separate from placebo on the primary depression endpoint, a significant negative result for the kappa antagonism hypothesis.
Safety
Dynorphin A is not used clinically and has no established human safety profile. Kappa agonism characteristically produces dysphoria, sedation, dissociation, hallucinations and diuresis. High spinal concentrations of dynorphin are neurotoxic in animal models through non-opioid mechanisms, an important caution against any notion of local administration. Material sold to consumers is unregulated and untested.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No UK marketing authorisation. Unlicensed substance with no lawful supply route for human consumption. |
| United States | No FDA approval and no active clinical programme for the peptide. Research reagent only. Its opioid pharmacology makes consumer marketing legally exposed. |
| WADA (sport) | Not individually named on the Prohibited List. Prohibited at all times under section S0 as a non-approved substance; opioid agonists generally are prohibited in competition under section S7. |
Questions
It is a major contributor. Stress drives prodynorphin expression through corticotropin-releasing factor, and kappa activation suppresses dopamine release in reward circuitry. Animal work supports this directly; human evidence is largely indirect.
An honest question with no comfortable answer. A kappa antagonist did engage the target and shift reward circuitry in an 89-patient imaging trial, but that never converted into clinical benefit: navacaprant did not beat placebo in phase 3 and aticaprant development was stopped. Mechanism alone was not sufficient.